# TowardPi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/towardpi

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.towardpi.com
- Total disclosed funding: $194M
- Latest round: Series E (Oct 13, 2025)
- Investors on record: 19

## About

Based in Beijing, China, and established in 2017, TowardPi (Beijing) Medical Technology Ltd., trading under the name TowardPi, operates as an ophthalmic equipment supplier that focuses on R&D and manufacture of optical coherence tomography (OCT) systems. In March 2026, TowardPi raised CNY 400 million in Pre-IPO funding led by Chengdu Science and Technology Venture Capital Group, with participation from Shunxi Fund, Sichuan Development Industry Led Equity Investment Fund Management, MPC, Beijing Guorui Investment, SinoKing Capital, Changkejin Investment, Tsingstone Capital, Tao Capital, Haoyue Fund.
The company's products can be categorized into BMizar 400KHz Full-Range SS-OCT, Yalkaid 100KHz Full-Range SS-OCT, Zalioth SS Optical Biometer, FoXue - Digital Navigation Microscope, etc. Its products are used in industries such as medical.
The company’s revenue is generated by providing ophthalmic medical products.

## Funding rounds

- Series E, Oct 13, 2025 — Beijing State-owned Capital Operation and Management, Tsinghua Innovation Ventures
- Series E, Mar 12, 2025, $69M — Qiming Venture Partners
- Series D, Jun 28, 2024, $28M — GTJA Investment Group, MPC
- Series C, Dec 20, 2022, $43M — Shanhai Capital, Tao Capital, Shanghai Sun Rock Capital Management, Suzhou Qingfen Capital Management, Haoyue Fund
- Series B, Dec 14, 2021, $31M — Fosun International, Changkejin  Investment, Winfast Holding, Tsinghua Innovation Ventures, Yuanhui Investment, Zhongfa Advanced Capital, Eyebright Medical Technology
- Series A, Jan 29, 2021, $23M — TusStar, THG Ventures, SinoKing Capital, Tsinghua Innovation Ventures, Zhongfa Advanced Capital
- Angel, Dec 12, 2017 — Tsinghua Innovation Ventures

## Investors

- Tsinghua Innovation Ventures (https://capitalatlas.ai/funds/tsinghua-innovation-ventures) — Angel, Series A, Series B, Series E
- TusStar (https://capitalatlas.ai/funds/tusstar) — Series A
- THG Ventures (https://capitalatlas.ai/funds/thg-ventures) — Series A
- SinoKing Capital (https://capitalatlas.ai/funds/sinoking-capital) — Series A
- Zhongfa Advanced Capital (https://capitalatlas.ai/funds/zhongfa-advanced-capital) — Series A, Series B
- Fosun International (https://capitalatlas.ai/funds/fosun-international) — Series B
- Changkejin  Investment — Series B
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series B
- Yuanhui Investment — Series B
- Eyebright Medical Technology — Series B
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series C
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series C
- Shanghai Sun Rock Capital Management (https://capitalatlas.ai/funds/shanghai-sun-rock-capital-management) — Series C
- Suzhou Qingfen Capital Management — Series C
- Haoyue Fund — Series C
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series D
- MPC — Series D
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series E
- Beijing State-owned Capital Operation and Management (https://capitalatlas.ai/funds/beijing-state-owned-capital-operation-and-management) — Series E